Scholar Rock, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersCambridge, MA
US patents29
SAM.gov UEIGLW8SVDWAF37
CAGE code12D74
Incorporated inDE
LEI549300Z1FLPGL4OWJ459
- development
- medicines
- Spinal Muscular Atrophy
- Cardiometabolic Disorders
- Fibrotic Diseases
Named on the company’s own website, read JUL 29, 2026
CareersCareers page — seen SEP 8, 2026
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
29 US patents granted 2016–2025, 20 of them in the five years to SEP 2025.
Pharmaceuticals 29
- LTBP complex-specific inhibitors of TGF-beta 1 and uses thereofUS 12,358,992 · granted JUL 15, 2025
- Selective and potent inhibitory antibodies of myostatin activationUS 12,338,279 · granted JUN 24, 2025
- RGMC-selective inhibitors and use thereofUS 12,297,262 · granted MAY 13, 2025
- TGFβ antibodies, methods and usesUS 12,281,159 · granted APR 22, 2025
- Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitorsUS 12,252,531 · granted MAR 18, 2025
Newest 5 shown · Granted to Scholar Rock, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Scholar Rock, INC. | Cambridge | MA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.